Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05841160 · ClinicalTrials.gov registry record · Phase 1
Thorough QT/QTc Study to Evaluate the Effects of Ecopipam (EBS-101) on Cardiac Repolarization
A Phase 1 study, sponsored by Emalex Biosciences.
- Completed
- Registry status
- Phase 1
- Development phase
- 29
- Enrollment target
NCT05841160: Completed Phase 1 study, sponsored by Emalex Biosciences.
NCT05841160 is a Phase 1 study that has completed, run by Emalex Biosciences. The registered enrollment target is 29 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (52% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05841160, a Phase 1 study, has completed, sponsored by Emalex Biosciences.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 29 participants
- Enrollment target
Study Summary
THOROUGH QT/QTc STUDY TO EVALUATE THE EFFECTS OF ECOPIPAM (EBS-101) ON CARDIAC REPOLARIZATION
Primary Outcome
ECGs and PK samples will be collected for up to 96 hours after each dose
Interventions
- DRUG Placebo
- DRUG Moxifloxacin
- DRUG Ecopipam Hydrochloride
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 29 participants |
| Start Date | 2023-03-15 |
| Est. Completion | 2023-05-12 |
| Phase | Phase 1 |
What the finished NCT05841160 record still lists
NCT05841160 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 29 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (52% lower).
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT05841160 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05841160 about?
NCT05841160 is a clinical study titled "Thorough QT/QTc Study to Evaluate the Effects of Ecopipam (EBS-101) on Cardiac Repolarization". THOROUGH QT/QTc STUDY TO EVALUATE THE EFFECTS OF ECOPIPAM (EBS-101) ON CARDIAC REPOLARIZATION
What is the current status of trial NCT05841160?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 29 participants. The study started on 2023-03-15. Estimated completion is 2023-05-12.
What interventions are being tested in trial NCT05841160?
The interventions under investigation include: Placebo (DRUG), Moxifloxacin (DRUG), Ecopipam Hydrochloride (DRUG).
Who is sponsoring clinical trial NCT05841160?
This trial is sponsored by Emalex Biosciences, which has 14 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05841160's enrollment target sits among peer trials
29 1440th of 2000 higher than 554 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02429557 · 29 participants · Phase 1
Hemodynamic Mechanisms of Abdominal Compression in the Treatment of Orthostatic Hypotension in Autonomic Failure
- NCT02568878 · 29 participants · Phase 3
Creatine for Depressed Male and Female Methamphetamine Users
- NCT03014401 · 29 participants · NA
The Effect of Adipose-Derived Stem Cells for Knee Osteoarthritis
- NCT03128996 · 29 participants · Phase 1
Reduced Intensity Conditioning and Familial HLA-Mismatched BMT for Non-Malignant Disorders
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI